Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2013 | Original Paper

The efficacy of nonestrogenic therapy to hot flashes in cancer patients under hormone manipulation therapy: a systematic review and meta-analysis

Authors: N. Yamaguchi, Y. Okajima, T. Fujii, A. Natori, D. Kobayashi

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2013

Abstract

Purpose

The incidence of hot flashes under hormone manipulation therapy is so high that this symptom caused by sex hormone blocking agents has been bothering patients and has a negative impact on their quality of life. Venlafaxine and gabapentin are most promising novel nonestrogenic agents to control the symptom. We seek to quatitatively summarize the efficacy of these novel agents.

Patients and methods

We conducted a meta-analysis of randomized controlled studies on the efficacy of venlafaxine/gabapentin to hot flashes in cancer patient under hormone deprivation therapies. A search for Medline, Embase, Cochrane Central Register of Controlled Trials, Ichushi, and Google Scholar yielded 733 citations, which were independently assessed by two authors. We estimated overall effect sizes and its 95 % confidence intervals (CI) for the efficacy of these agents compared with the controls with standardized mean difference.

Results

A total of 5 studies involving 588 cancer patients with hot flashes finally fulfilled the predefined inclusion criteria. Overall effect size of the efficacy of venlafaxine/gabapentin was −0.630 (95 % CI [−0.801, −0.459]).

Conclusion

Venlafaxine/gabapentin significantly improved hot flashes in cancer patients under hormone manipulation therapies.

Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490PubMedCrossRef

Biglia N, Torta R, Roagna R et al (2005) Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas 52(1):78–85PubMedCrossRef

Biglia N, Sgandurra P, Peano E et al (2009) Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric 12(4):310–318PubMedCrossRef

Boekhout AH, Vincent AD, Dalesio OB et al (2011) Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 29(29):3862–3868PubMedCrossRef

Bordeleau L, Pritchard KI, Loprinzi CL et al (2010) Venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 28(35):5147–5152PubMedCrossRef

Buijs C, Mom CH, Willemse PH et al (2009) Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 115(3):573–580PubMedCrossRef

Carpenter JS, Andrykowski MA, Cordova M et al (1998) Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer 82(9):1682–1691PubMedCrossRef

Carpenter JS, Storniolo AM, Johns S et al (2007) Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 12(1):124–135PubMedCrossRef

Charig CR, Rundle JS (1989) Flushing long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 33(3):175–178PubMedCrossRef

Chlebowski RT, Kuller LH, Prentice RL et al (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587PubMedCrossRef

Couzi RJ, Helzisouer KJ, Fetting JH (1995) Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13(11):2737–2744PubMed

Furukawa TA, Barbui C, Cipriani A et al (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59(1):7–10PubMedCrossRef

Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537PubMedCrossRef

Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560PubMedCrossRef

Ioannidis JP, Trikalinos TA (2007) The appropriateness of asymmetry tests for publication bias in meta-analysis: a large study. CMAJ 176(8):1091–1096PubMedCrossRef

Irani J, Salomon L, Oba R et al (2010) Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 11(2):147–154PubMedCrossRef

Loibi S, Schwedler K, von Minckwitz G et al (2007) Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients–a double-blind, randomized study. Ann Oncol 18(4):689–693

Loprinzi CL, Kugler JW, Sloan JA et al (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356(9247):2059–2063PubMedCrossRef

Loprinzi CL, Dueck AC, Khoyratty BS et al (2009) A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 20(3):542–549PubMedCrossRef

McCowan C, Shearer J, Donnan PT et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768PubMedCrossRef

Moher D, Liberati A, Tetzlaff J et al (2009) PRISMA Group.preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med 6(7):e1000097PubMedCrossRef

Pandya KJ, Morrow GR, Roscoe JA et al (2005) Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 366(9488):818–824PubMedCrossRef

Rada G, Capurro D, Pantoja T et al (2010) Non-hormonal interventions for hot flashes in women with a history of breast cancer. Cochrane Database Syst Rev 8(9):CD004923

Rhoden EL, Averbeck MA, Teloken PE (2008) Androgen replacement in men undergoing treatment for prostate cancer. J Sex Med 5(9):2202–2208PubMedCrossRef

Savard MH, Savard J, Quesnel C et al (2009) The influence of breast cancer treatment on the occurrence of hot flashes. J Pain Symptom Manage 37(4):687–697PubMedCrossRef

Siegel R, Desantis C, Virgo K et al. (2012) Cancer treatment and survivorship statistics CA Cancer J Clin 2012 Published on June 14 2012 doi: 10.3322/caac.21149

Sloan JA, Loprinzi CL, Novotny PJ et al (2001) Methodologic lessons learned from hot flash studies. J Clin Oncol 19(23):4280–4290PubMed

Walker EM, Rodriguez AI, Kohn B et al (2010) Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 28(4):634–640PubMedCrossRef

Title: The efficacy of nonestrogenic therapy to hot flashes in cancer patients under hormone manipulation therapy: a systematic review and meta-analysis
Authors: N. Yamaguchi
Y. Okajima
T. Fujii
A. Natori
D. Kobayashi
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1491-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2013

Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma

Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients

The prognostic significance of Jun transcription factors in ovarian cancer

Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma

Laparoscopic versus open total gastrectomy with D2 dissection for gastric cancer: a meta-analysis

Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials